Truist Securities Maintains Buy on Pacira BioSciences, Lowers Price Target to $55
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Les Sulewski has maintained a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX), but lowered the price target from $60 to $55.
August 04, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacira BioSciences' price target has been lowered from $60 to $55 by Truist Securities, though the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100